SD | Griffith University
A large Swedish nationwide study was conducted whereby researchers, led by Professor Mark Taylor (above)
from Griffith’s School of Medicine and Dentistry, analysed data from nearly 15,000 people with bipolar disorder who were prescribed GLP-1 medications over a 15-year period. “People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalisation compared with periods when they were not taking GLP-1 medicines,” Professor Taylor said.